On the other hand, some of them—metformin, GLP-1 RAs, and SGLT2i—have a potential detrimental effect on the risk of sarcopenia since they help to decrease body weight by reducing energy intake or increasing glucose excretion by glycosuria, negatively impacting on muscle mass. The gene discussed is GCG; the disease is sarcopenia.